Sunil Rao1, Ronald C Gentile. 1. From the *Department of Ophthalmology, The New York Eye and Ear Infirmary, New York, New York; and †Department of Ophthalmology, New York Medical College, Valhalla, New York.
Abstract
PURPOSE: To report the effect of off-label use of bevacizumab (Avastin) in the treatment of choroidal neovascularization associated with a choroidal osteoma. METHODS: Interventional case report examining antivascular endothelial growth factor therapy used for choroidal neovascularization complicating a choroidal osteoma. RESULTS: A 24-year-old man with a choroidal osteoma presented with metamorphopsia and decreased vision in his left eye of 20/60. Clinical examination, fluorescein angiography, B-scan ultrasonography, and optical coherence tomography revealed a well-circumscribed macular choroidal osteoma with overlying subretinal hemorrhage and a choroidal neovascular membrane. The patient was treated with a series of 3 intravitreal bevacizumab (Avastin) injections (1.25 mg/0.05 mL) performed at baseline, 1 month, and 2 months. Treatment resulted in resolution of subretinal hemorrhage and fluid with improvement in visual acuity to 20/30 at the 5-month follow-up. CONCLUSION: Intravitreal bevacizumab seems to be a promising treatment for choroidal neovascularization (CNV) associated with choroidal osteomas.
PURPOSE: To report the effect of off-label use of bevacizumab (Avastin) in the treatment of choroidal neovascularization associated with a choroidal osteoma. METHODS: Interventional case report examining antivascular endothelial growth factor therapy used for choroidal neovascularization complicating a choroidal osteoma. RESULTS: A 24-year-old man with a choroidal osteoma presented with metamorphopsia and decreased vision in his left eye of 20/60. Clinical examination, fluorescein angiography, B-scan ultrasonography, and optical coherence tomography revealed a well-circumscribed macular choroidal osteoma with overlying subretinal hemorrhage and a choroidal neovascular membrane. The patient was treated with a series of 3 intravitreal bevacizumab (Avastin) injections (1.25 mg/0.05 mL) performed at baseline, 1 month, and 2 months. Treatment resulted in resolution of subretinal hemorrhage and fluid with improvement in visual acuity to 20/30 at the 5-month follow-up. CONCLUSION: Intravitreal bevacizumab seems to be a promising treatment for choroidal neovascularization (CNV) associated with choroidal osteomas.
Authors: V P Papastefanou; M Pefkianaki; L Al Harby; A K Arora; V M L Cohen; R M Andrews; M S Sagoo Journal: Eye (Lond) Date: 2016-04-01 Impact factor: 3.775
Authors: Ahmad M Mansour; J Fernando Arevalo; Eman Al Kahtani; Hernando Zegarra; Emad Abboud; Rajiv Anand; Hamid Ahmadieh; Robert A Sisk; Salman Mirza; Samuray Tuncer; Amparo Navea Tejerina; Jorge Mataix; Francisco J Ascaso; Jose S Pulido; Rainer Guthoff; Winfried Goebel; Young Jung Roh; Alay S Banker; Ronald C Gentile; Isabel Alonso Martinez; Rodney Morris; Neeraj Panday; Park Jung Min; Emilie Mercé; Timothy Y Y Lai; Vicky Massoud; Nicola G Ghazi Journal: J Ophthalmol Date: 2014-07-23 Impact factor: 1.909